EANS-News: SYGNIS Pharma AG / SYGNIS announces last patient treated in its AXIS 2 efficacy Study

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

Heidelberg (euro adhoc) - SYGNIS announces last patient treated in
its AXIS 2 efficacy Study

Heidelberg, 03 November 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech
company researching and developing innovative CNS treatments, today
announced the completion of the treatment for its randomized,
double-blind study designed to demonstrate the efficacy of AX200
for the treatment of patients with acute ischemic stroke (AXIS
2). 328 patients have been treated across eight European countries.

AX200 has a dual mechanism-of-action in the treatment of acute
stroke, stopping neuronal cell death and promoting the regeneration
of the damaged CNS tissue, providing a new, first-in-class
approach to treating stroke patients.

Dr. Frank Rathgeb, Chief Medical Officer of SYGNIS, commented: "We
are pleased to have completed treatment in our clinical phase II
efficacy study and are now finalizing the data collection. We expect
to report initial findings of the AXIS 2 Study towards the end
of 2011".

Going forward, SYGNIS will review the options for the development and
marketing of AX200. Possibilities include continuing development by
the company itself or through outlicensing to external parties. In
addition, SYGNIS will consider developing AX200 together with a
partner.

About the AXIS 2 Study

The AXIS 2 Study started in mid 2009 in about 80 renowned stroke
centres in Germany, Austria, Belgium, Sweden, Spain, the Czech
Republic, Poland and the Slovak Republic. The Study included 328
stroke patients, the one half of which has been treated with AX200
and the other half with a placebo. Patients were enrolled up to
nine hours after suffering a stroke and have been treated by
infusion for a period of three days. Also patients were included into
the AXIS 2 Study, who received drug-based lysis therapy using
rt-PA prior to the treatment with AX200. AX200 is one of the most
advanced drug candidates for the treatment of acute stroke
worldwide.

About SYGNIS Pharma

SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty
pharmaceutical company listed in the Prime Standard of the
Frankfurt Stock Exchange. The Company is focused on the research
and development of innovative therapies for the treatment of
disorders of the Central Nervous System. SYGNIS´ core projects are
currently Acute Stroke for which SYGNIS´ lead clinical programme is
AX200, as well as the preclinical KIBRA-project for the treatment of
different forms of dementia. All these disorders are characterized
by the fact that, as the disease progresses, nerve cells are
damaged and die. Although there is great medical demand, there
are currently no or only inadequate treatment options available.
Furthermore, a key element of the sustainable value creation of the
Company is the expansion of the product pipeline, which will be
secured through its own developments as well as in-licensing and
acquisitions.

For further information please contact:

SYGNIS Pharma AG

Dr. Franz-Werner Haas
Senior Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media Contact:
Julia Phillips
FTI Consulting
Tel.: +44 (0) 20 7269 7187

###

Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English